MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Apomorphine"

  • 2022 International Congress

    Apomorphine Sublingual Film Versus Subcutaneous Apomorphine in the Treatment of OFF Episodes in Parkinson’s Disease: Results From an Assessment of Patient Satisfaction

    J. Schwarz, C. Carroll, G. Ebersbach, J. Kulisevsky, A. Tessitore, I. Zhang, A. Bowling, S. Wu, E. Pappert, A. Thach (Oberbayern, Germany)

    Objective: Evaluate treatment satisfaction with apomorphine sublingual film (SL-APO) vs subcutaneous apomorphine (SC-APO) for the treatment of OFF episodes in patients with Parkinson’s disease (PD).…
  • 2022 International Congress

    Apomorphine Sublingual Film Titrated at Home in Patients With Parkinson’s Disease and OFF Episodes: Results From an Open-Label, Randomized, Crossover Study

    J. Kassubek, F. Stocchi, E. Balaguer, S. Isaacson, I. Zhang, A. Bowling, S. Wu, E. Pappert (Ulm, Germany)

    Objective: Evaluate the ability of patients with Parkinson’s disease (PD) and OFF episodes to achieve an effective and tolerable FULL ON dose of apomorphine sublingual…
  • 2022 International Congress

    Safety and Tolerability of Apomorphine Sublingual Film and Subcutaneous Apomorphine for the Treatment of OFF Episodes in Parkinson’s Disease

    O. Rascol, W. Poewe, F. Stocchi, R. Chaudhuri, J. Kassubek, L. Lopez Manzanares, V. Leta, I. Zhang, A. Bowling, S. Wu, E. Pappert (Toulouse, France)

    Objective: Evaluate safety and tolerability of apomorphine sublingual film (SL-APO) vs subcutaneous apomorphine (SC-APO) for the treatment of OFF episodes in patients with Parkinson’s disease…
  • 2022 International Congress

    Paliperidone induced neuroleptic malignant syndrome treated with electroconvulsive therapy and continuous apomorphine: A case report

    M. Gultekin, S. Benli (Kayseri, Turkey)

    Objective: Neuroleptic malignant syndrome (NMS) is a neurological emergency that is often induced by antipsychotic drugs. NMS may be mortal if left untreated. Background: In…
  • 2022 International Congress

    USE OF NIGHT TIME CONTINUOUS SUBCUTANEOUS INFUSION OF APOMORPHINE (NCSAI) IN ADVANCED PARKINSON’S DISEASE: A SERIES OF 37 CASES.

    AK. Vargas Mendoza, B. López López, M. Díaz Castela, J. Molina Gil, P. Zunzunegui Arroyo, A. Criado Antón, ME. Suárez Sanmartín, C. García Fernández (Oviedo, Spain)

    Objective: The aim of this study is to evaluate the feasibility, efficacy and safety of NCSAI administration in patients with Advanced Parkinson disease (APD). Background:…
  • 2022 International Congress

    Expanding the armamentarium of clinical use of apomorphine in movement disorders.

    S. Bansal, JR. Chai, M. Jog (London, Canada)

    Objective: To demonstrate the use of subcutaneous(SC) apomorphine injections in suspected untreated dopamine responsive conditions. Background: Apomorphine is a dopamine agonist historically used in dopamine…
  • 2022 International Congress

    Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Incremental Motor Improvement Observed with Increasing Doses

    S. Isaacson, I. Zhang, E. Pappert, A. Bowling (Boca Raton, USA)

    Objective: Evaluate magnitude of motor improvement with increasing doses of apomorphine sublingual film (SL-APO) in patients with Parkinson’s disease (PD) and OFF episodes. Background: Identifying…
  • 2022 International Congress

    Use of apomorphine infusion pump in the elderly population : a 5 years follw up study on efficacy, safety and tolerability in a cohort bases study

    C. Borrue- Fernandez, M. Mata, C. Jimeno, M. Almarcha (San Sebastian Reyes, Spain)

    Objective: Evaluate the efficacy, tolerability and safety of subcutaneous apomorphine infusion in elderly patients with advanced Parkinson's disease in a five years follow up cohort. Background: Continuous infusion by subcutaneous apomorphine pump has…
  • 2022 International Congress

    May apomorphine be helpful for the axial symptoms of Parkinson’s Disease?

    A. Alonso-Canovas, P. Perez Torre, G. Sanchez Diez, A. Patiño Paton, N. Gonzalez, I. Parees Moreno, JC. Martinez Castrillo (Madrid, Spain)

    Objective: To assess the effect of continuous subcutaneous infusion of apomorphine on axial symptoms of Parkinson Disease. Background: Axial symptoms of Parkinson’s Disease may be…
  • 2022 International Congress

    Lateral shifting from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in the treatment of advanced idiopathic Parkinson’s disease (PD): Case series

    M. Abu Al-Melh, M. Farghal, N. Abdelall (Ahmadi governorate, Kuwait)

    Objective: To report our experience with transitioning from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in two patients with advanced idiopathic Parkinson’s disease (PD). Background: Device-assisted…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 12
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • An atypical and interesting feature of Parkinson´s disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley